🦉 The Cancer Vaccine That Targets Its Own Resistance Cancer vaccines aim to train T cells to recognize tumors. But what happens when the resulting immune attack activates new mechanisms of resistance? In pancreatic cancer models, a KRAS G12D vaccine triggered strong T-cell responses, yet surviving tumors showed increased Wnt signaling. Further experiments revealed a potential feedback loop: inflammatory cytokines released by activated T cells induced WNT5a expression in cancer cells and cancer-associated fibroblasts. Researchers turned that response into a second target. Their dual-antigen vaccine, WKC-VAX, targets both mutant KRAS and WNT5a. In mice, it increased cytotoxic T-cell infiltration, reduced suppressive stromal components and tumor burden, and improved survival when combined with PD-1 blockade. The broader idea is compelling: cancer vaccines might be designed not only against the original tumor, but also against the resistance mechanisms that immune activation helps reveal. WNT5a's causal role in resistance remains unproven, and clinical efficacy and safety have yet to be established. #immunotherapy #T_cell nature.com/articles/s41423-0…